The objective of this paper is to validate prostate specific antigen (PSA) density (PSAD) routine use to enhance PSA specificity in men with normal digital rectal examination and intermediate PSA values. It is a retrospective study of 235 men from a prostate cancer (PCa) screening program. All of them presented PSA values between 4 and 10 ng/ml, normal digital rectal examination, and a transrectal ultrasound (TRUS) guided biopsy available (PSA ! 4 ng/ml as the sole criterion for biopsy). Multivariate analysis failed to demonstrate higher PSAD values in men with PCa. PSAD cutoff points higher than 0.07 ng/ml per cc were considered as unacceptable, with less than 95% sensitivity. When a cutoff point of 0.15 was considered, as many as 30.6% of the cancers were missed. In conclusion we cannot recommend the use of this parameter for the above mentioned purpose.
Introduction
Prostate specific antigen (PSA) is to date the most accurate serum marker for cancer of the prostate (PCa). However, it is not cancer specific and when intermediate levels (4 -10 ng/ml) are obtained, an important overlap exists between benign prostatic hyperplasia (BPH) and PCa, in terms of biopsy outcome. Therefore, many prostate biopsies are indicated to distinguish between these two pathologies.
Several methods have been developed to overcome this inconvenience, including PSA velocity (PSAV), 1 agespecific PSA, 2 or per cent free PSA. 3 The concept of PSA density (PSAD) was first described by Benson et al, 4, 5 and is defined as the quotient of serum PSA level divided by the prostate volume estimated by means of transrectal ultrasound (TRUS). Several studies have recommended the use of this parameter to enhance PSA specificity when intermediate levels of this marker are present. 5 -10 Therefore, many unnecesary biopsies could be avoided without a significant decrease of the cancer detection rate. Unfortunately, such results have not been reproduced by other authors. 11 -15 The objective of the present study is to validate PSAD clinical use to enhance PSA specificity in healthy men with normal digital rectal examination and intermediate PSA values.
Patients and methods
From a PCa screening population of 5200 men, 235 were studied retrospectively. Criteria for selection were to present PSA values (Hybritech Tandem-E 1 , San Diego, CA) within intermediate range (4 -10 ng/ml), a normal digital rectal examination (DRE), and a sextant TRUS guided prostate biopsy available. The only criterium for biopsy in the selected population was a serum PSA greater or equal to 4 ng/ml, regardless of PSAD values or any other parameter (men biopsied by means of any other parameter than PSA alone were excluded).
All prostate biopsies were performed by means of TRUS (Siemens Sonoline SI-450, and a biplanal 7.5 MHz transducer). Sextant biopsy specimens were taken from each patient, and also additional cores were directed towards any suspicious echogenicity, when present.
Total prostate volume was calculated using the formula: Prostate volume ¼ 0.52 6 longitudinal dimension 6 anteroposterior dimension 6 transverse dimension. 16 PSAD was defined as serum total PSA value divided by total prostate volume. 4, 5 PSAV was also calculated when more than one PSA measurement was available [(last PSAÀprevious PSA)/ time elapsed (years)]. 1 When three PSA measurements were available, the average PSAV was calculated.
Parameters taken into account included: age, PSA level, prostate volume, presence of suspicious TRUS echogenicities, PSAD, and PSAV. To address the hypothetical association of these factors with the presence of PCa in prostate biopsies, univariate analysis was performed with the aid of w 2 analysis for categorical variables and with Mann-Whitney nonparametric analysis for continuous variables. Multivariate analysis was also performed by means of logistic regression analysis.
Results
The age of the 235 studied men ranged from 47 to 83 y, mean 62.2, mean standard error (s.e.) 6.58, and median 62. Mean PSA value was 6 ng/ml (s.e. 1.61, median 5.6). Total prostate volume ranged from 12 to 209.2 cc (mean 43.1, s.e. 24.01, median 36.5).
A total of 83 men from this sample had more than one PSA measurement available (57 of them had two, and 26 had three). Time intervals between measurements ranged from 165 to 1290 days, with a median of 445 days (first interval), and 1096 days (second interval). PSAV ranged from À9.29 to 5.56 ng/ml per year (mean À0.30, s.e. 1.92, median À0.317).
Thirty-six cancers were detected in the studied population (15% overall rate of cancer detection -Mediterranean country). Thirty-three were clinically localised, two locally advanced and one with regional nodal disease (non-metastatic). Four of them presented with a Gleason score greater than 7. TRUS showed abnormal findings in 40 men. PSAD values ranged from 0.03 to 0.39 ng/ml per cc (mean 0.17, s.e. 0.08, median 0.163).
Univariate analysis showed no differences in age or PSA values between cancer and noncancer groups ( Table  1) . On the other hand, lower prostate volumes (P ¼ 0.003), higher PSAD (P ¼ 0.003), and higher PSAV (P ¼ 0.031) were found in men with PCa. An almost significant relationship was found between cancer and TRUS abnormalities: 10/36 (27.8%) in cancer patients, vs 30/ 199 (15.1%) in noncancer men (P ¼ 0.062).
None of the study parameters showed any significant relationship with biopsy results after multivariate analysis: age (P ¼ 0.147), TRUS abnormalities (P ¼ 0.701), PSA level (within the studied range 4 -10 ng/ml, P ¼ 0.094). Prostate volume (P ¼ 0.07), PSAD (P ¼ 0.066), and PSAV (P ¼ 0.055) were the only variables that nearly reached the same value as predictors of biopsy results.
PSAD was also analysed taking into account several cutoffs, from 0.05 to 0.25 ng/ml per cc (Table 2) . Cutoff points higher than 0.07 ng/ml per cc were considered as unacceptable, with less than 95% sensitivity, missing more than 5% of the cancers that could have been detected using PSA as the sole criterion for biopsy. If a PSAD cutoff point of 0.07 was considered, only 17 biopsies out of 235 (7.2%) would be avoided (92.8% of the studied men were above this limit). Area under ROC curve was highest when PSAD of 0.05 was used as cutoff point, but almost all (98.7%) of the studied population had a PSAD value below this limit. With regard to PSAV, if biopsies were prompted when higher than 0.75 /ng/ml per year, performance would be somewhat better than PSAD: 80% sensitivity (missed one cancer out of five), 83% specificity, and 24% positive predictive value.
Discussion and conclusions
In this study we tried to address the role of PSAD in one specific group of men undergoing screening for PCa: patients with normal digital rectal examination and PSA levels ranging from 4 to 10 ng/ml. The use of this parameter is supposed to avoid a significant amount of unnecesary biopsies without leaving an excessive number of cancers undiagnosed. 5 Unfortunately, multivariate analysis failed to demonstrate any significant association between PSAD and biopsy results in our hands. Moreover, if the recommended cutoff of PSAD > 0.15 is used to prompt biopsy (instead of performing biopsies based solely on serum PSA level greater or equal to 4 ng/ml), as much as 30.6% of the cancers would remain undetected. No practical improvement in diagnostic performance was observed with other cutoff points ( Table 2 ). In conclusion, in our setting these findings show this parameter to have no additional value when compared to PSA alone.
Some studies have reached conclusions in the opposite direction: Benson et al 5 noted a significant difference in mean PSAD values between cancer (0.297) and noncancer (0.208) patients in a study with 533 men. Unlike the present study, criterium for biopsy was not a serum PSA between 4 and 10 ng/ml, so many patients did not undergo biopsy, therefore it was difficult to reach definite conclusions. Seaman et al 6 also recommended the use of PSAD in men with intermediate PSA levels and normal rectal examination. Unfortunately, this study was a continuation of Benson's with a similar design, and again many men were not biopsied. Bazinet et al 7 examined 142 patients with normal DRE and intermediate PSA values, and concluded that PSAD could be used to avoid unnecesary biopsies (optimal cutoff point 0.15) without missing a significant number of cancers. Some other authors reached similar conclusions. 8 -10 On the other hand, some studies offered similar conclusions to what was observed in our experience: Catalona et al found that when using a PSAD cutoff point of 0.15 as recommended in the literature, more than half of the cancers would have been missed. 11, 12 Other authors have found similar results. 13 -15 Alternative methods are needed. PSAV has been also proposed to enhance specificity and its use is recommended. 17 In our study, this parameter fared slightly better than PSAD. Unfortunately, the number of patients with multiple PSA measurements available in this study was limited, and the ability of PSAV to discriminate between cancer and benign biopsies was not significant in multivariate analysis. Moreover, the convenience of using long-time intervals between measurements (1.5 -2 y) and a minimum of three PSA draws to decide to biopsy or not, make this parameter difficult to use in a clinical basis. 17, 18 Performance of other alternatives, such as per cent free PSA, 2, 12 or PSA adjusted for transition zone volume 19 seems to be promising.
We conclude that PSA density was not able to distinguish between cancer and noncancer patients. Moreover, if biopsies were done accordingly to the recommended cutoff point of 0.15, an unacceptable number of cancers would be missed. We therefore cannot recommend the use of this parameter to enhance specificity in men with normal rectal examination and intermediate PSA values when screening for prostate cancer.
